- AdventHealth has partnered with SpotRx pharmacy technologies to debut two pharmacy kiosks in Hillsborough and Marion Counties
- The kiosks purport to cut down on wait times between the time of being prescribed a medication and being able to pick it up at a pharmacy
- A home delivery service has also been rolled out, increasing patient access to life-saving medications
AdventHealth, one of Florida’s largest health providers, has partnered with SpotRX to debut two pharmacy kiosks in Hillsborough and Marion Counties. The pair of kiosks aim to cut down on prescription wait times and increase accessibility for those needing medications.
The kiosks will provide acute and chronic medications, over-the-counter products as well as creams, ointments, eye drops, and test strips. The kiosks, however, will not house controlled substances such as diazepam or oxycodone.
“We are committed to making it easy for our patients by finding innovative ways to deliver health care that fits into busy schedules,” said John Johannessen, Senior Executive Officer of Non-Acute, AdventHealth West Florida Division. “Our partnership with SpotRx provides another time-saving convenience at our Care Pavilions so patients can get the care they need and not have to make another stop before they get home.”
Alongside kiosk services, patients can now utilize the embedded pharmacy model to request home delivery services. Using the model, those seeking treatment throughAdventHealth patients will receive immediate access to prescriptions, next-day home delivery for all prescriptions and over-the-counter medications, and instant access to SpotRx pharmacists via kiosk or phone.
“We are excited to partner with AdventHealth and expand patient access to our differentiated pharmacy solutions in Florida. We are additionally pleased to leverage our new hub pharmacy in Tampa to service these clinics,” said Mark Doerr, Chief Executive Officer of MedAvail. “We look forward to serving AdventHealth patients through this collaboration and broadening our footprint in Florida where we see a tremendous opportunity and need for SpotRx.”